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Use of herbal medicine is popular among cancer patients. This study aimed to explore the coprescription of CHM and WM
among prostate cancer patients in Taiwan. This cross-sectional retrospective study used a population-based database containing
one million beneﬁciaries of National Health Insurance. Claims and prescriptions were analyzed. In 2007, 218 (22.4%) prostate
cancer patients were CHM users. Among CHM users, 200 (91.7%) patients with 5618 (79.5%) CHM prescriptions were on
coprescription of CHM and WM. A total of 484 types of CHM and 930 types of WM were used. The most commonly used
CHMs on coprescription were Shu Jing Huo Xue Tang, Ma Zi Ren Wan, and Xue Fu Zhu Yu Tang. The most commonly used WMs
on coprescription were magnesium oxide, amlodipine, and aspirin. The average number of prescriptions per user per year was
261.2 versus 151.7 in all (P<0.001), 123.6 versus 76.9 in WM (P = 0.033), and 34.8 versus 5.1 in CHM (P<0.001) for patients
with and without coprescription, respectively. In conclusion, use of CHM among prostate cancer patients was popular in Taiwan.
Most CHMs were used with WM concurrently. The potential drug-herb interactions should be investigated, especially for patients
with more prescriptions.
1.Introduction
Complementary and alternative medicine (CAM) has be-
come increasingly popular worldwide in the recent decades
[1–3]. Herbal medicine is one of the most popular types of
CAM. Previous studies showed 8.4–26.5% of prostate can-
cer patients using herbal remedies [4–8]. Chinese herbal
medicine (CHM) has been used among the Chinese popu-
lation for thousands of years and is gradually accepted in the
West. Due to the possibility of drug-herb interactions, it is
important to know which Chinese herbal medicine is most
frequently used by prostate cancer patients. However, there
is limited information on this issue.
National Health Insurance (NHI), which covers both
Western and Chinese medicines, has been implemented in
Taiwan since 1995. By 2010, over 99% of the 23 million
residents are enrolled in the program. Beneﬁciaries are free
to choose the types of medical services they prefer. NHI
coverage of Chinese medicine services includes CHM, acu-
puncture, and traumatology manipulative therapies.
The National Health Insurance Research Database
(NHIRD) provides registration and claim datasets for re-
search. In this study, we used NHIRD to explore the frequen-
cy and pattern of CHM use among prostate cancer patients.
Coprescriptions of CHM and Western medications (WM)
were also assessed.
2. Methods
2.1. Data Sources. This is a cross-sectional retrospective
study using Longitudinal Health Insurance Database 2000
(LHID2000), which was obtained from NHIRD. LHID2000
contains all the original claim data of 1,000,000 individuals
randomly sampled from the 23 million beneﬁciaries of the
NHI. There is no signiﬁcant diﬀerence in the distribution2 Evidence-Based Complementary and Alternative Medicine
of age, gender and insured amount between the patients in
the LHID2000 and the original NHIRD. Data in NHIRD
that could be used to identify patients or care providers,
including medical institutions and physicians, is scrambled
before being sent to the National Health Research Institutes
for database construction and is further encrypted before
being released to each researcher. Since all the data had
been deidentiﬁed, approval of institutional review board was
exempt.
2.2. Study Samples. Under the NHI regulations, each claim
for reimbursement is required to record up to three diag-
nosis codes in the format of International Classiﬁcation of
Diseases, Ninth Revision, Clinical modiﬁcation (ICD-9-
CM). Prostate cancer patients were identiﬁed from the ﬁle
of ambulatory service of the year 2007 from LHID2000 with
ICD-9-CM code 185. Claims and corresponding prescrip-
tions of these prostate cancer patients in LHID2000 were
then retrieved for analysis. Coprescription of WM and CHM
wasdeﬁnedasthecasesinwhichthetwotypesofmedication
were prescribed within overlapped prescription duration.
2.3. Statistics. The database software ASIQ 12.5.7 (Sybase
Inc, Dublin, Calif, USA) was used for data extraction and
linking.ThedatawereanalyzedusingSPSSforWindowsVer-
sion 13.0 (SPSS Inc, Chicago, ILL, USA). The distribution
andfrequencyofeachcategoryofvariableswereexaminedby
Chi-square tests. A P value of less than 0.05 was considered
statistically signiﬁcant.
3. Results
A total of 972 prostate cancer patients were identiﬁed in the
ambulatory service ﬁle of the year 2007 from LHID2000,
with 42859 visits and 183108 prescriptions. Among them,
218 (22.4%) patients used CM, with 1361 visits (average 6.2
visits per user) and 7070 CHM prescriptions (average 5.2
prescriptions per visit). A total of 970 (99.8%) patients used
Western medicine, with 32520 visits (33.5 visits per user)
and 100736 WM prescriptions (average 3.1 prescriptions per
visit).
3.1. Patient Demographics. The demographics are presented
inTable 1.Themedianagewas75.4innoncoprescriptionpa-
tients and 73.7 in coprescription patients. A higher propor-
tionofcoprescription patients werefoundat theagebetween
50 and 79 (P = 0.194).
With regard to income (insured payroll-related
amounts), a higher portion of patients with monthly income
of US$609–1218 was found in the group of coprescription
(P = 0.18) (US$1 = NT$32.842).
In terms of insured regions, there was a higher propor-
tion of coprescription patients registered in central Taiwan
(P = 0.005).
As to insured unit, a higher proportion of coprescription
patients were farmers and ﬁshermen (P = 0.53).
3.2. Prescriptions. The coprescription patients had more
prescriptionsthanthenoncoprescriptionpatients(Figure 1).
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Figure 1: Average number of prescriptions per user per year of
patients with and without coprescription. The average number of
prescriptions per user per year was 261.2 versus 151.7 in all (P<
0.001), 123.6 versus 76.9 in WM (P = 0.033), and 34.8 versus 5.1
in CHM (P<0.001) for patients with and without coprescription,
respectively. Data were expressed as the mean ± SD. WM: Western
medications; CHM: Chinese herbal medicine; All: WM and CHM.
The average number of prescriptions per user per year was
261.2 versus 151.7 in all (P<0.001), 123.6 versus 76.9 in
WM (P = 0.033), and 34.8 versus 5.1 in CHM (P<0.001)
for patients with and without coprescription, respectively.
3.3. Prescriptions of Chinese Herbal Medicine. There were
7070CHM prescriptions. A total of 484 types of CHM were
used. The most frequently prescribed CHMs were Shu Jing
Huo Xue Tang, Ma Zi Ren Wan, and Ji Sheng Shen Qi Wan
(Table 2). Most CHM prescriptions were used for non-
prostate-cancerdiseases/conditions.Therewere1510(21.4%)
prescriptionswithdiagnosiscodeofprostatecancerand5560
(78.6%) prescriptions without diagnosis code of prostate
cancer.
3.4. Prescriptions of Western Medications. The WM prescrip-
tions amounted to 100736. A total of 930 types of WMs were
used. The most frequently prescribed WM were acetamino-
phen, aspirin, and tamsulosin (Table 2). Most WM prescrip-
tions were used for nonprostate-cancer diseases/conditions.
There were 26699 (26.5%) prescriptions with diagnosis code
of prostate cancer and 74037 (73.5%) prescriptions without
diagnosis code of prostate cancer.
3.5. Coprescription of CHM and WM. Among CHM users,
200 (91.7%) patients had coprescriptions of CHM and WM.
A total of 5618 (79.5%) CHM prescriptions were used with
WM concurrently. In coprescribed prescriptions, 468 types
of CHM and 506 types of WM were found. The most
frequently used CHMs in coprescription were Shu Jing Huo
Xue Tang, Ma Zi Ren Wan, and Xue Fu Zhu Yu Tang.Evidence-Based Complementary and Alternative Medicine 3
Table 1: Patient demographics.
Characteristics Patients without coprescription Patients with coprescription P value
Total % Total %
No. of patients 772 200
Age 0.194
Median (years) 75.8 73.7
<50 17 2.2 5 2.5
50’s 59 7.6 21 10.5
60’s 155 20.1 46 23.0
70’s 296 38.3 81 40.5
>80 245 31.7 47 23.5
Insured amount (US$/month) 0.18
0 220 28.5 55 27.5
1–608 286 37.0 67 33.5
609–1218 194 25.1 64 32.0
>1218 72 9.3 13 6.5
Missing data 0 0.0 1 0.5
Insured region 0.005
Northern Taiwan 472 61.1 99 49.5
Central Taiwan 108 14.0 46 23.0
Southern Taiwan 175 22.7 51 25.5
Eastern Taiwan & Oﬀshore islands 17 2.2 3 1.5
Missing data 0 0.0 1 0.5
Insured unit 0.0
Employees of government, school, enterprises or institutions 88 11.4 21 10.5 0.53
Members of occupational unions, alien seamen 25 3.2 4 2.0
Farmers, Fishermen 171 22.2 54 27.0
Low-income households 3 0.4 2 1.0
Veterans, other regional populationa 265 34.3 63 31.5
Dependentb 220 28.5 55 27.5
Missing data 0 0.0 1 0.5
aAll family members are unemployed and not low-income households.
bPeople are unemployed or under 20 years of age and have insured family member.
Table 2: Top ten most common prescriptions among prostate cancer patients.
Rank Western medications (n = 100736) Chinese herbal medications (n = 7070)
Products (compound) n % Products (Chinese name) n %
1 Acetaminophen 3467 3.4 Shu Jing Huo Xue Tang 111 1.6
2 Aspirin 2366 2.3 Ma Zi Ren Wan 99 1.4
3 Tamsulosin 1928 1.9 Ji Sheng Shen Qi Wan 89 1.3
4 Magnesium oxide 1779 1.8 Yan Hu Suo 75 1.1
5 Cyproterone acetate 1610 1.6 Xue Fu Zhu Yu Tang 73 1.0
6 Amlodipine 1600 1.6 Ping Wei Shen 70 1.0
7 Doxazosin 1258 1.2 Da Huang 68 1.0
8 Sennoside 1242 1.2 Du Huo Ji Sheng Tang 67 0.9
9 Metformin 1230 1.2 Wu Wei Zi 66 0.9
Zhi Bai Di Huang Wan 66 0.9
10 Sodium chloride 1153 1.1 Jie Geng 64 0.94 Evidence-Based Complementary and Alternative Medicine
Table 3: Top ten most common CHMs and WMs used in coprescription among prostate cancer patients.
Rank Western medications (n = 5369) Chinese herbal medications (n = 5617)
Products (compound) n % Products (Chinese name) n %
1 Magnesium oxide 138 2.6 Shu Jing Huo Xue Tang 102 1.8
2 Amlodipine 136 2.5 Ma Zi Ren Wan 97 1.7
3 Aspirin 120 2.2 Xue Fu Zhu Yu Tang 66 1.2
4 Acetaminophen 111 2.1 Zhi Bai Di Huang Wan 63 1.1
5 Tamsulosin 98 1.8 Da Huang 62 1.1
Du Huo Ji Sheng Tang 62 1.1
6 Metformin 75 1.4 Jie Geng 59 1.1
7 Cyproterone acetate 71 1.3 Ping Wei Shen 58 1.0
8 Ambroxol 65 1.2 Yan Hu Suo 57 1.0
Terazosin 65 1.2
9 Sennoside 61 1.1 Wu Wei Zi 53 0.9
Ji Sheng Shen Qi Wan 53 0.9
10 Dipyridamole 59 1.1 Niu Xi 50 0.9
The most frequently used WMs in coprescription were
magnesium oxide, amlodipine, and aspirin (Table 3).
The prescriptions of CHM and WM for cancer and non-
cancer diseases were quite diﬀerent. For visits with diagnosis
code of prostate cancer, the most common types of CHM
for coprescription were Bai Mao Gen, Ma Zi Ren Wan,
and Da Huang and the most common types of WM for
coprescription were cyproterone acetate, tamsulosin, and
magnesium oxide (Table 4).
Among the 237 prostate cancer patients who used cy-
proterone acetate, 29 (12.2%) patients used CHM and cy-
proterone acetate concurrently, with 665 (41.4%) CHM pre-
scriptions.
4. Discussion
Use of herbal medicine among prostate cancer patients is
popular. Yet there is little information readily available on
what CHM products are used by prostate cancer patients.
This is the ﬁrst population-based study to provide the em-
pirical evidence of coprescription of CHM and WM among
prostate cancer patients. With over 90% coverage rate of
NHI, the NHIRD is representative of the whole population
in Taiwan. The complete claims of prescriptions in diﬀerent
medical institutes of the sample patients were obtained
for analysis. Our results demonstrated that 22.4% prostate
cancer patients used CHM. A total of 484 types of CHM
wereused.MostprescribedCHMhaveseldombeenreported
for prostate cancer in literature even though they were pop-
ularly used in this study. Most CHM prescriptions (79.5%)
were used with WM concurrently. The potential drug-herb
interactionsshouldbeexplored.Thisstudyprovidedrelevant
information for the subsequent basic and clinical studies.
In Taiwan, only licensed Chinese medicine physicians
are qualiﬁed for reimbursement of CM services under NHI.
Services of Chinese medicine include CHM, acupuncture,
and traumatology manipulative therapies. Reimbursement
for CHM is limited to concentrated Chinese medicines
registered as “only for dispensing a prescription” and
“prescription only used by physicians (Chinese medicine).”
Compounding concentrated Chinese medicines shall be
listed in “Standard formula of clinically common used Chi-
nese medicine” edited by central health authority. All NHI-
covered CHMs should be manufactured by approved good
manufacturing practice (GMP) Chinese medicine compa-
nies. Therefore, the quality control and quality assurance
of CHM used in NHI are under surveillance by the central
health authority in Taiwan. According to the regulations,
Chinese medicine physicians are certiﬁed to prescribe CHM
but not WM. Western doctors are certiﬁed to prescribe WM
but not CHM.
The prevalence of CHM is much higher than that in our
previous cross-sectional study [9] and is consistent with our
previous long-term trends studies [10]. Our previous cross-
sectionalstudyonlyaccountedCMvisitswithdiagnosiscode
of prostate cancer (ICD-9-CM code 185) and found 2.6%
prostate cancer patients used CM services. Our previous
long-term trends study explored CM use among prostate
cancer patients under NHI from 1996 to 2008 and found
that the prevalence of CM use in each cross-sectional year
increased slightly from 24.9% to 25.6%. Most CM visits
(92.7%) were noncancer-speciﬁc. The most frequently used
CM therapy was CHM (72.8% to 78.8%). In this study, all
CM visits of prostate cancer patients were selected including
claims with and without diagnosis code of prostate cancer.
This study found only 21.4% prescriptions with diagnosis
code of prostate cancer. Most prostate cancer patients
usedCHMfornonprostate-cancerdiseases/conditions.Since
most CHM prescriptions had been given without diagnosis
code of prostate cancer, it is very likely that many Chinese
medical physicians were not aware of the diagnosis of
prostate cancer of these patients.
This study found the patients with coprescription had
more prescriptions than the patients without coprescription.
Prostate cancer is particularly common among elderly men.
Given the higher prevalence of multiple health conditions
in elderly, inappropriate medication use and adverse drug
events (ADEs) are substantial problems in this populationEvidence-Based Complementary and Alternative Medicine 5
Table 4: Top ten most common Western medications and Chinese herbal medications used in coprescription of claims with diagnosis code
of prostate cancer.
Rank
Western medications (n = 1532) Chinese herbal medications (n = 1146)
Products
(compound) n % Products
(Chinese name) Ingredients (Latin name) n %
1 Cyproterone acetate 70 4.6 Bai Mao Gen Rhizoma Imperatae Cylindricae 40 3.5
2 Tamsulosin 63 4.1 Ma Zi Ren Wan
Fructus Cannabis, Radix Paeoniae, Fructus Aurantii
Immaturus, Radix et Rhizoma Rhei, Cortex Magnoliae
Oﬃcinalis, Semen Armeniaccae Amarum
35 3.1
3 Magnesium oxide 60 3.9 Da Huang Radix et Rhizoma Rhei 31 2.7
Sheng Di Huang Radix Rehmanniae 31 2.7
4 Imipramine 50 3.3 Zuo Gui Wan
Radix Rehmanniae, Glutinosae Conquitae, Fructus Corni
Oﬃcinalis, Fructus Lycii, Colla Cornus Cervi, Semen
Cuscutae Chinensis, Radix Dioscoreae Oppositae, Colla
Carapacis et Plastri Testudinis, Radix Achyranthis
Bidentatae
29 2.5
5 Terazosin 49 3.2 Niu Xi Radix Achyranthis Bidentatae 28 2.4
6 Leuprolide acetate 43 2.8 Che Qian Zi Semen Plantaginis 27 2.4
7 Tolterodine
L-tartrate 40 2.6 Yu Mi Xu Stigma Maydis 26 2.3
Zhu Ru Caulis Bambusae in Taeniis 26 2.3
8 Doxazosin 34 2.2 Gui Zhi Fu Ling Wan Ramulus Cinnamomi, Sclerotium Poriae Cocos, Cortex
Moutan Radicis, Semen Persicae, Radix Paeoniae Rubra 26 2.3
9 Sennoside 30 2.0 Gui Lu Er Xian Jiao Colla Carapacis et Plastri Testudinis, Colla Cornus Cervi,
Fructus Lycii, Radix Ginseng 23 2.0
10 Alfuzosin 29 1.9 Shu Jing Huo Xue
Tang
Radix Glycyrrhizae, Radix Angelicae Sinensis, Radix
Paeoniae Alba, Radix Rehmanniae, Rhizoma
Atractylodis, Radix Cyathulae, Pericarpium Citri
Reticulatae, Semen Persicae, Radix et Rhizoma
Clematidis, Rhizoma Chuanxiong, Radix Stephaniae
Tetrandrae, Rhizoma et Radix Notopterygii, Radix
Saposhnikoviae, Radix Angelicae Dahuricae, Gelatinum
Plastri Testudinis, Poria, Rhizoma Zingiberis Recens
22 1.9
[11, 12]. The number of medications consumed is the main
risk factor of inappropriate medication use and ADE [11,
12]. The relationship between number of prescriptions and
ADE risk is strong [13, 14]. Our study found much higher
average prescriptions in the study population than previous
study. The risk of ADE needs further study.
A total of 484 types of CHM were used in this study. The
most frequently used CHMs were Shu Jing Huo Xue Tang,
Ma Zi Ren Wan, and Ji Sheng Shen Qi Wan. According to
the concept of Chinese medicine, Shu Jing Huo Xue Tang
is used for serous arthritis of the knees, lower back pain,
sciatica, numbness in the lower limbs, and edema of the legs.
This is consistent with acetaminophen and aspirin being the
most commonly used WM. Ma Zi Ren Wan is a formula
and is used to lubricate the intestines and consequently pro-
motes bowel movement. Ji Sheng Shen Qi Wan is used for
kidney Yang deﬁciency, heaviness at lumbar, foot edema, and
diﬃculty in urination. The concept of prescribing CHM is
diﬀerent from that of prescribing WM. According to Chinese
medicinal principles, the development of cancer is viewed as
the result of an imbalance of the whole body-mind network.
The kidney is the organ that maintains balance of the entire
urological system. Therefore, Chinese medicine physicians
will prescribe herbs or formulas to restore the balance of yin
and yang in the kidneys rather than to treat cancer directly.
ThereisnoconsensusonthestandardCHMregimensfor
prostate cancer currently. This study revealed the complexity
ofCHMuseamongprostatecancerpatientsasthemostcom-
mon CHM represents only 111 out of 7070 in total (1.6%).
This reﬂected the multiple symptoms of prostate cancer pa-
tients presented to CM physicians and the disagreement in
prescriptionpolicyamongCMphysicians.ThetheoryofCM
is very distinct from that of WM. CM physicians treat symp-
toms rather than diseases. For prostate cancer patients who
experienced diﬀerent symptoms, CM physicians would pre-
scribe diﬀerent CHM regimens. Besides, one CHM prescrip-
tion usually combines several single herbs and formulas to
balance the toxic eﬀects. In the choice of herbs and formulas,
there are also many alternative combinations with similar
eﬀects. Therefore, CHM use for prostate cancer is complex.
The top ten most common CMH prescriptions among
prostate cancer patients contained 43 types of single herbs.
Some herbs were more commonly used than others. Since
these herbs were so popular, they might help to improve
quality of life among prostate cancer patients. Their eﬀects
in prostate cancer deserve further investigation. On the other6 Evidence-Based Complementary and Alternative Medicine
hand, the risk of drug-herb interactions of these herbs would
be higher. Licorice (Radix Glycyrrhizae)a n dN i uX i( Radix
Achyranthis Bidentatae) were used in four of the top ten
CMH prescriptions. Licorice is a very popular CHM and
commonlyusedinherbalformulaeto“harmonize”theother
ingredients. Licorice was used for the treatment of peptic
ulcer, constipation, cough, and other diseases. Clinical and
experimental studies suggested that it has several other use-
ful pharmacological properties such as antiinﬂammatory,
antiviral, antimicrobial, antioxidative, anticancer activities,
and immunomodulatory, hepatoprotective, and cardiopro-
tective eﬀects [15, 16]. Licorice was reported to interact with
angiotensin-converting enzyme (ACE) inhibitors, diuretics,
aspirin, digoxin, corticosteroids, insulin, and laxatives [17–
19]. Niu Xi is used for expeling blood stasis, nourishing the
liver and kidney, and strengthening the bones and muscles.
Niu Xi was reported to have antiinﬂammatory, analgesic and
antihypertensive eﬀects [20]. The use of Niu Xi along with
diuretics and antihypertensive drugs may result in additive
eﬀects.
Most CHM products are used for centuries in Chinese
population and are generally safe if CHM products are used
under the traditional rules. Our study found that most CHM
prescriptions (79.5%) were used with WM concurrently.
Appropriate integration of CHM and WM may have syn-
ergistic eﬀects; in consequence, treatment outcome is en-
hanced and side eﬀects are suppressed. However, the poten-
tial and signiﬁcance of interactions between most CHM and
WM are not widely recognized. Recent studies reported that
some herbs had the potential to cause drug-herb interactions
with anticancer drugs or other medications [21–25]. Among
coprescribed prescriptions, 468 types of CHM and 506
t y p e so fW Mw e r eu s e d .M a n yC H Mp r o d u c t sw e r eh e r b a l
formulas, containing a variety of herbs. The most frequently
used CHMs in coprescription were Shu Jing Huo Xue Tang,
M aZ iR e nW a n ,a n dX u eF uZ h uY uT a n g .T h em o s tf r e -
quently used WMs in coprescription were magnesium oxide,
amlodipine, and aspirin. Adverse interactions between herbs
and analgesic drugs were reported, such as acetaminophen
andaspirin[26].ConcurrentuseofGinseng(PanaxGinseng)
and amlodipine has the potential to cause adverse interac-
tions [27]. Ginseng may also cause additive blood glucose-
lowering eﬀects when used in combination with antidiabetic
drugs and thus increase the risk of hypoglycemia [19].
Dong Quai (Radix Angelicae Sinensis), Dan Shen (Radix
Salviae Miltiorrhizae), Chinese wolfberry (Fructus Lycii)a n d
Ginseng were reported to have interactions with warfarin
[28]. Ginger (Rhizoma Zingiberis Recens) has the potential
to interact pharmacologically with aspirin and coumarin
derivatives [28]. Ginkgo was reported to have possible anti-
coagulant eﬀects, which would interfere with chemotherapy
and radiation therapy [29]. Fu Ling (Poria)w a sr e p o r t e dt o
interact with diuretics [19, 30].
The prescriptions of CHM and WM for cancer and non-
cancer diseases were quite diﬀerent. For visits with diagnosis
codeofprostatecancer,themostfrequentlyusedCHMprod-
uctsincoprescriptionwereBaiMaoGen(RhizomaImperatae
Cylindricae), Ma Zi Ren Wan, and Da Huang (Radix et
Rhizoma Rhei) and the most frequently coprescribed WM
were cyproterone acetate, tamsulosin, and magnesium oxide.
Cyproterone acetate is oral nonsteroidal antiandrogen and
used in the treatment of prostate cancer. Among 237 prostate
cancer patients who used cyproterone acetate, 29 (12.2%)
patients used CHM and cyproterone acetate concurrently,
with 665 (41.4%) CHM prescriptions. Interactions of herbs
with antiestrogenic drugs have been reported [31, 32].
Licorice and Dong Quai (Radix Angelicae Sinensis) have the
potential of interactions with estrogen [19]. However, there
is little information on the interactions between herbs and
antiandrogen drugs. Because antiandrogen drugs had been
used for anticancer purpose for years, the potential interac-
tions of antiandrogen drugs with herbs are important prob-
lems. Further investigation on this issue is necessary.
This study found coprescription patients tended to be at
age 50–79 (no signiﬁcant diﬀerence), with a middle level
of monthly income of US$609–1218 (no signiﬁcant diﬀer-
ence), living in central Taiwan (statistical signiﬁcance), and
belonging to the career category of farmers or ﬁshermen (no
signiﬁcant diﬀerence). The manpower of CM physicians was
geographical maldistributed in Taiwan. There are more CM
physicians and institutes per person in central Taiwan than
in other regions [33]. A past study also showed that “usable
resources” was an important factor which inﬂuenced the CM
purchasing behavior [34]. Because most CHM prescriptions
were used with WM concurrently, patients in central Taiwan
showed a higher rate of coprescription.
Thestrengthofthisstudyisthatthedataisrepresentative
and reliable. Since the NHI covered 99% of Taiwan’s 23
million residents and over 90% of the medical institutes, the
NHIRD is representative of the general population. NHIRD
provides clear and reliable records and avoids recall bias
in answering survey questions on past utilization. Besides,
reimbursements for Chinese medicine were restricted to li-
censed Chinese medicine physicians who practiced at hos-
pitals or clinics. Our study assessed the utilization of legally
recognized Chinese medicine, the most important part of
CAM in Taiwan’s health system. Our previous study showed
prostate cancer patients visited Western medicine physicians
at hospitals and visited Chinese medicine physicians at clin-
ics. NHIRD provides all the claim dataset for study and is a
good tool to investigate concurrent use of medications pre-
scribed by diﬀerent medical institutes.
There are several limitations in this study. Because NHI
only covered ambulatory services for Chinese medicine, this
study only accounted claims of ambulatory services but not
inpatients services. Medications at admission and postdis-
charge medications were not accounted. Besides, insurance-
covered CHM is restricted to concentrated Chinese herbal
medicine. Raw and over-the-counter herbal products were
not covered by NHI and therefore not accounted in this
study. CHM is very popular in Taiwan. Liu’s study surveyed
64 cancer patients and found that only about one-thirds of
CHM products were obtained from Chinese medical clinics
(withlicensedpractitioner)[35].Itisestimatedthatthesame
or double amount of CHM was used by the patients them-
selves. The prevalence of concurrent use of CHM and
WM was expected to be higher. Finally, the NHIRD is
established primarily for administrative purposes. ClinicalEvidence-Based Complementary and Alternative Medicine 7
characteristics, including staging and biochemical data were
not available. The outcome and side eﬀects of CHM use were
not assessed in this study.
In conclusion, use of Chinese herbal medicine among
prostate cancer patients was popular in Taiwan. Most Chi-
nese herbal medicines were used with Western medications
concurrently.Thepotentialdrug-herbinteractionsshouldbe
investigated, especially for patients with more prescriptions.
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